Abstract:

Bicyclol was the first chemical new drug independently developed by China and used to treat inflammatory liver injury. After bicyclol was put on the market, a large amount evidences of basic researches and evidence-based medicine had been accumulated in the anti-inflammatory and hepatoprotective treatment of liver diseases caused by various causes. In the aspect of basic research, bicyclol had showed the anti-inflammatory and hepatoprotective effects and related molecular mechanisms in models such as the chemical, immune, fatty and fibrotic liver injury and partial liver resection and ischemia-reperfusion injury. In terms of clinical application, several clinical studies had evaluated the efficacy and safety of bicyclol in the treatment of chronic viral hepatitis, fatty liver disease, drug-induced liver injury and other liver diseases. Analysis of large sample data in the real world furtherly showed that bicyclol had good security. According to the evidence-based medical evidence and basic research results accumulated by bicyclol in the treatment of liver inflammatory injury in the past five years, the "Expert recommendations on clinical application of bicyclol tablets" in 2014 was revised and improved. Then this "Expert consensus on clinical application of bicyclol" is formed in order to provide clinicians with more scientific, rigorous, comprehensive and practical reference opinions on the administration of bicyclol, so as to better serve the clinical practice.

Key words: Bicyclol, Liver function injury, Clinical application, Pharmacological action, Expert consensus